Relapsing-remitting multiple sclerosis
MONDO:0005314The most common clinical variant of multiple sclerosis, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see optic neuritis), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
283 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New MS drug trial for kids: could ocrelizumab help?
Disease control Not yet recruitingThis study tests a drug called ocrelizumab in children and teens aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). The goal is to see how the drug moves through the body, if it is safe, and how it affects the immune system. Participants will receive the drug as a sh…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug hope for kids with MS: ublituximab trial launches
Disease control Not yet recruitingThis study tests the drug ublituximab in children aged 10 to 18 with relapsing multiple sclerosis (MS). It compares ublituximab to another drug, fingolimod, to see which better controls relapses. The trial involves 240 participants and will also monitor long-term safety and effec…
Phase: PHASE2, PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental drug aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests an experimental drug called STR-P005 in people with autoimmune diseases that have come back or not improved with standard treatments. The drug is given through an IV in multiple doses. The main goal is to check safety and see how the body handles the drug. …
Phase: NA • Sponsor: Starna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
AI-Powered tool aims to sharpen MS treatment choices
Disease control Not yet recruitingThis study tests a computer program called PRIMUS that helps neurologists choose treatments for people with relapsing-remitting multiple sclerosis (MS). The tool uses data from past patients to predict how the disease might progress under different therapies. Doctors in some clin…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gentle exercise with cuffs may boost muscle in MS patients
Disease control Not yet recruitingThis study tests whether adding blood flow restriction cuffs to light leg exercises can help people with relapsing-remitting multiple sclerosis build bigger, stronger thigh muscles. Thirty participants will do the same exercise twice a week for 8 weeks, but some will have the cuf…
Phase: NA • Sponsor: Hanifi Bal • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
MS patients switch drugs to save immune defenses
Disease control Not yet recruitingThis study follows 115 adults with multiple sclerosis who are switching from ocrelizumab to ofatumumab because their antibody levels dropped. Researchers want to see if the switch stops or slows that decline over 24 months. The goal is to better manage immune health while still t…
Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
MS patients may soon get a simpler shot option
Disease control Not yet recruitingThis study looks at whether people with multiple sclerosis can safely switch from their current anti-CD20 therapy to a new under-the-skin version of ocrelizumab. About 100 participants will be followed for up to 48 weeks to see if brain lesions stay stable and if they are satisfi…
Phase: PHASE4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug STR-P005 aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests a new drug called STR-P005 in 18 people with autoimmune diseases that have not responded to standard treatments. The main goal is to check safety and find the best dose. Participants receive the drug by infusion in different schedules, and researchers will …
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New MS drug trial uses Super-Powered MRI to see inside the brain
Disease control Not yet recruitingThis study tests an experimental drug called remibrutinib in 20 people with relapsing or progressive multiple sclerosis (MS). Participants take the drug twice daily for 2 years and undergo powerful 7T MRI scans to measure changes in brain volume, lesions, and tissue health. The g…
Phase: PHASE2 • Sponsor: Moein Amin • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Lifestyle makeover tested as MS symptom fighter
Disease control Not yet recruitingThis study tests whether a structured 12-week program focusing on nutrition, exercise, sleep, and stress management can improve fatigue, physical function, and quality of life in people with relapsing-remitting multiple sclerosis. Thirty participants will first be observed for 12…
Phase: NA • Sponsor: New York University Abu Dhabi • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New CAR-T therapy targets tough MS cases in early safety trial
Disease control Not yet recruitingThis early study tests a new treatment called S103 (BCMA-CAR T cells) in 9 adults with progressive or hard-to-treat multiple sclerosis (MS). The main goal is to see if the treatment is safe and to find the best dose. Researchers will also look for early signs that it might help c…
Phase: PHASE1 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental cell therapy takes on multiple sclerosis
Disease control Not yet recruitingThis early-stage trial tests a new treatment for multiple sclerosis (MS) that combines a drug called ofatumumab with NK042, a therapy made from immune cells donated by healthy people. The study will include 20 adults with different types of MS and will primarily check for safety …
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to hit MS early and hard
Disease control Not yet recruitingThis study tests whether giving two strong medications one after the other—rituximab then cladribine—is safe and works well for people with relapsing-remitting multiple sclerosis (MS). Sixty adults aged 18 to 50 with active MS within the last year will receive the treatment and b…
Phase: PHASE2 • Sponsor: Uppsala University • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
MS drug delivery showdown: belly vs. thigh, pen vs. syringe
Disease control Not yet recruitingThis study tests a drug called ublituximab, given as a shot under the skin, in 350 people with relapsing multiple sclerosis. Researchers want to see how the drug moves through the body when injected in different spots (like the belly or thigh) and whether an autoinjector pen work…
Phase: PHASE2 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for kids with MS: safer drug combo aims to stop relapses
Disease control Not yet recruitingThis study tests two drugs, diroximel fumarate and dimethyl fumarate, in children with relapsing multiple sclerosis. About 185 kids will be split by weight and randomly assigned to one of the drugs or a standard treatment (fingolimod). The goal is to see which drug is safer and b…
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could an allergy pill help heal the brain in MS? new trial aims to find out
Disease control Not yet recruitingThis study tests whether clemastine fumarate, an over-the-counter allergy medication, can repair damaged nerve insulation (myelin) in people with multiple sclerosis. About 44 adults with relapsing-remitting MS will receive either the drug or a placebo for 3 months, then all will …
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Ancient herb granule takes on MS in new clinical trial
Disease control Not yet recruitingThis trial tests whether a traditional Chinese medicine called Yishen Daluo Yin granule can help people with relapsing-remitting multiple sclerosis. About 152 participants will take either the granule or a placebo twice a day for 24 weeks. The main goal is to see if the treatment…
Phase: NA • Sponsor: Ying Gao • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could a common supplement tame multiple sclerosis?
Disease control Not yet recruitingThis study tests whether adding taurine, a natural amino acid, to standard multiple sclerosis (MS) medications can improve outcomes. About 80 adults with relapsing-remitting MS will either continue their usual drugs or add daily taurine for 24 months. Researchers will track brain…
Phase: PHASE2 • Sponsor: Sichuan Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could one antibiotic dose before tooth pulling prevent infections in Immune-Weakened patients?
Prevention Not yet recruitingThis study tests whether a single dose of amoxicillin before a simple tooth extraction can prevent infections in people with autoimmune rheumatic diseases who are on immune-suppressing medications. Researchers will compare infection rates between those who get the antibiotic and …
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:07 UTC
-
Nurse-Led video calls aim to empower MS patients
Symptom relief Not yet recruitingThis study tests a six-month personalized telenursing program for 110 adults with multiple sclerosis. Participants receive monthly educational videos and nurse-led video calls to help them better understand their health and navigate the healthcare system. The goal is to improve h…
Phase: NA • Sponsor: G. d'Annunzio University • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Could Low-Oxygen breathing supercharge gait therapy for MS?
Symptom relief Not yet recruitingThis study tests whether breathing low-oxygen air for short periods right before walking training helps people with multiple sclerosis walk better and farther. Thirty-five participants will receive either the low-oxygen breathing or a sham (placebo) version, followed by treadmill…
Phase: NA • Sponsor: Shirley Ryan AbilityLab • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Could magnetic pulses ease MS depression and fatigue?
Symptom relief Not yet recruitingThis pilot study tests whether repetitive transcranial magnetic stimulation (rTMS) is safe and helpful for depression and fatigue in adults with multiple sclerosis (MS). About 20 participants will receive daily rTMS sessions for 5 days, with assessments before, after, and at a 4-…
Phase: PHASE1 • Sponsor: University of Calgary • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Could a zapping cap boost memory? small study tests brain stimulation for cognitive decline
Symptom relief Not yet recruitingThis pilot study will test whether a non-invasive brain stimulation technique called transcranial alternating current stimulation (tACS) can improve working memory in 30 adults with mild cognitive impairment or traumatic brain injury. Participants will receive low-level electrica…
Phase: NA • Sponsor: Sunnybrook Health Sciences Centre • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Exercise may shield the brain in MS patients, new trial hopes to prove
Symptom relief Not yet recruitingThis study will test whether a 12-week progressive resistance training program can improve brain health and daily function in people with relapsing-remitting multiple sclerosis. Thirty participants will be randomly assigned to either an exercise group or a control group. Research…
Phase: NA • Sponsor: Firat University • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
New therapy aims to steady the steps of MS patients
Symptom relief Not yet recruitingThis study tests whether sensory integration therapy can improve walking stability and quality of life in people with multiple sclerosis (MS). About 44 adults with relapsing-remitting MS will be randomly assigned to receive either the therapy or standard care. The therapy uses sp…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
Exercise may ease sexual dysfunction in MS, small study hopes
Symptom relief Not yet recruitingThis study tests whether an internet-based physical activity program can improve sexual dysfunction in women with relapsing-remitting multiple sclerosis. Thirty women with MS and sexual problems will use a website and have video chats with a coach to increase their physical activ…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
Can exercise tame the immune system in MS? new study investigates
Knowledge-focused Not yet recruitingThis study looks at how different types of exercise—aerobic and resistance training—affect the immune system and physical abilities in people with relapsing-remitting multiple sclerosis (MS). Researchers will measure changes in blood markers of inflammation and functional tests l…
Phase: NA • Sponsor: Seda Saka • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Can when you eat protect your brain from MS?
Knowledge-focused Not yet recruitingThis study looks at whether the time of day you eat can affect brain health in people with multiple sclerosis. Twenty-two adults with MS will follow a daily eating schedule for a set period. Researchers will measure markers of nerve health and inflammation in the blood. A small g…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
MS mystery: do some relapses hide from MRI scans?
Knowledge-focused Not yet recruitingThis study looks at whether people with relapsing-remitting multiple sclerosis (RRMS) can have a relapse—new or worsening symptoms—without any visible inflammation on an MRI scan. Researchers will follow 136 adults who are having a suspected relapse, performing early brain and sp…
Phase: NA • Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Exercise may shield MS brains from damage, small trial hopes to show
Knowledge-focused Not yet recruitingThis study will test whether a 12-week progressive resistance training program can improve brain health in people with relapsing-remitting multiple sclerosis. Researchers will measure brain volume and a nerve damage marker in the blood. The trial involves 26 participants and aims…
Phase: NA • Sponsor: Firat University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Can hospitals boost vaccine access for the most vulnerable?
Knowledge-focused Not yet recruitingThis study will test a new way to offer vaccines to vulnerable patients—those with chronic diseases or weakened immune systems—during hospital visits. Researchers will see if offering, prescribing, and giving vaccines in the hospital increases how many people get vaccinated. The …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
MS treatment failure: the hidden emotional toll on patients
Knowledge-focused Not yet recruitingThis study looks at how treatment failure impacts the quality of life, anxiety, depression, and daily activities of 150 adults with relapsing-remitting multiple sclerosis. Researchers will use questionnaires to measure patients' well-being and their experience with care. The goal…
Sponsor: University Hospital, Caen • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
AI takes on MS: new study aims to predict disease progression
Knowledge-focused Not yet recruitingThis study will collect health data and samples from 100 people with multiple sclerosis over several years. Researchers will use artificial intelligence and data science to find patterns that could help predict how the disease will progress. The goal is to eventually personalize …
Sponsor: Luxembourg Institute of Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
New study aims to find which MS drug better fights fatigue
Knowledge-focused Not yet recruitingThis study will follow 100 adults with multiple sclerosis who are starting either teriflunomide or dimethyl fumarate as part of their routine care. Over 12 months, researchers will measure how well participants can walk and think during sustained activities, along with their repo…
Sponsor: TC Erciyes University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Hidden heart risks in kids with brain conditions?
Knowledge-focused Not yet recruitingThis study looks at 70 children aged 1 month to 18 years who have neurological disorders like epilepsy, migraine, or stroke. Researchers will use echocardiograms and ECGs to check for hidden heart problems. The goal is to understand if heart issues are common in these children an…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 26, 2026 19:21 UTC